Form D · Biotechnology
Nuclein, LLC
Austin, TX · CIK 0001787352
Offering snapshot reported Oct 27, 2026 · SEC filing
- Reported sold
- $15.7M Offering amount: $26.1M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 4, 2026 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$1,295,000 → $15,650,488
- Reported investors2 → 25
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 27, 2026 | Amendment | $15,650,488 | $14,355,488vs Jun 22, 2026 | 25 | SEC filing |
| Aug 14, 2026 | Amendment | $9,253,488 | $7,958,488vs Jun 22, 2026 | 15 | SEC filing |
| Jun 22, 2026 | Initial | $1,295,000 | No comparison | 2 | SEC filing |
| Apr 27, 2026 | Amendment | $19,065,157 | $4,161,157vs Dec 17, 2025 | 49 | SEC filing |
| Feb 5, 2026 | Amendment | $9,392,180 | No comparison | 34 | SEC filing |
| Dec 17, 2025 | Amendment | $14,904,000 | $5,125,000vs Oct 14, 2025 | 42 | SEC filing |
| Oct 14, 2025 | Amendment | $9,779,000 | No comparison | 37 | SEC filing |
| Jun 30, 2025 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Feb 3, 2025 | Initial | $750,000 | No comparison | 3 | SEC filing |
| Aug 5, 2024 | Amendment | $8,788,151 | No comparison | 18 | SEC filing |
| Nov 17, 2023 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Mar 23, 2023 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jul 12, 2022 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 19, 2021 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Feb 18, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Sep 10, 2019 | Initial | $420,012 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-588046
Source: Form D, filed Oct 27, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alan Blake | Director, Executive |
| Douglas Bryant | Director |
| John Butler | Director |
| Sanjay Chandra | Director |
| Richard Crockett | Director |
| William Cunningham | Director |
| Walter Narajowski | Director |
| David Shockley | Director |
| H. David Shockley | Director |
| Jeffrey Stukuls | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
8305 Cross Park Dr
Austin, TX, 78754
Austin, TX, 78754